Efficacy and safety of tofacitinib in moderate and severe ulcerative colitis in real clinical practice: three years of observation

Efficacy and safety of tofacitinib in moderate and severe ulcerative colitis in real clinical practice: three years of observation

Introduction. Tofacitinib is the first member of a new class of targeted synthetic anti-inflammatory drugs for the treatment of ulcerative colitis (UC). The article presents a three-year Russian experience of tofacitinib use for the treatment of moderate and severe UC.Aim of the study. To evaluate t...

Full description

Bibliographic Details
Main Authors: O. V. Knyazev, A. V. Kagramanova, A. A. Lishchinskaya, I. A. Li, D. V. Podolskaya, T. V. Shkurko, B. A. Nanaeva, T. L. Aleksandrov, T. A. Baranova, I. A. Tishaeva, M. Yu. Zvyaglova, A. I. Parfenov
Format: Article
Language:Russian
Published: Remedium Group LLC 2021-10-01
Series:Медицинский совет
Subjects:
biological therapy
inflammatory bowel disease
janus kinase [jak] inhibitors
tofacitinib
ulcerative colitis
Online Access:https://www.med-sovet.pro/jour/article/view/6415

Internet

https://www.med-sovet.pro/jour/article/view/6415

Similar Items